Janus Henderson Group PLC Trims Holdings in Mesa Laboratories, Inc. $MLAB

Janus Henderson Group PLC lowered its stake in shares of Mesa Laboratories, Inc. (NASDAQ:MLAB) by 40.5% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 69,401 shares of the medical instruments supplier’s stock after selling 47,241 shares during the quarter. Janus Henderson Group PLC’s holdings in Mesa Laboratories were worth $6,136,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in MLAB. Royal Bank of Canada raised its holdings in Mesa Laboratories by 1.2% in the first quarter. Royal Bank of Canada now owns 30,772 shares of the medical instruments supplier’s stock valued at $3,652,000 after acquiring an additional 353 shares in the last quarter. Jacobs Levy Equity Management Inc. acquired a new position in Mesa Laboratories during the 1st quarter worth $335,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Mesa Laboratories by 4.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 3,068 shares of the medical instruments supplier’s stock worth $364,000 after acquiring an additional 143 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Mesa Laboratories by 3.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 19,977 shares of the medical instruments supplier’s stock worth $2,370,000 after purchasing an additional 685 shares during the last quarter. Finally, American Century Companies Inc. increased its position in shares of Mesa Laboratories by 1.5% in the 2nd quarter. American Century Companies Inc. now owns 13,431 shares of the medical instruments supplier’s stock worth $1,265,000 after purchasing an additional 194 shares during the last quarter. Institutional investors own 90.60% of the company’s stock.

Mesa Laboratories Price Performance

Shares of NASDAQ MLAB opened at $101.01 on Friday. Mesa Laboratories, Inc. has a twelve month low of $58.83 and a twelve month high of $113.99. The company has a current ratio of 1.72, a quick ratio of 1.29 and a debt-to-equity ratio of 0.78. The company has a market capitalization of $565.66 million, a price-to-earnings ratio of 84.18 and a beta of 0.92. The business has a 50 day simple moving average of $100.31 and a 200-day simple moving average of $95.10.

Mesa Laboratories (NASDAQ:MLAB) last announced its quarterly earnings data on Wednesday, May 27th. The medical instruments supplier reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.78 by ($0.25). Mesa Laboratories had a return on equity of 20.96% and a net margin of 2.69%.The firm had revenue of $63.72 million for the quarter, compared to the consensus estimate of $65.21 million. During the same quarter last year, the business earned ($1.31) earnings per share.

Mesa Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 15th. Shareholders of record on Monday, August 31st will be issued a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Monday, August 31st. Mesa Laboratories’s dividend payout ratio is 53.33%.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings cut shares of Mesa Laboratories from a “sell (d+)” rating to a “sell (d)” rating in a research report on Wednesday, June 3rd. Two equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Reduce” and a consensus target price of $94.00.

Insider Transactions at Mesa Laboratories

In other news, CAO Lyndsey Elizabeth Crennen sold 442 shares of the firm’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $89.50, for a total value of $39,559.00. Following the transaction, the chief accounting officer directly owned 2,020 shares in the company, valued at approximately $180,790. This trade represents a 17.95% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Brian David Archbold sold 2,516 shares of Mesa Laboratories stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $89.50, for a total transaction of $225,182.00. Following the completion of the transaction, the senior vice president directly owned 6,377 shares of the company’s stock, valued at $570,741.50. This trade represents a 28.29% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 8,277 shares of company stock worth $770,122. 2.80% of the stock is currently owned by insiders.

About Mesa Laboratories

Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.